Fig 1: Identification of the prognostic and potential biological value of PCBP1. A Heatmap of differentially expressed genes between cancer and adjacent tissues in LUAD patients and the early death group and long-term survival group. B Kaplan–Meier survival curves of overall survival between high PCBP1 expression and low PCBP1 expression patients from TCGA and GSE19188. C PCBP1 expression between patients with distant metastasis and patients without metastasis. D PCBP1 expression in LUAD patients with different TNM stages. E IHC staining of human LUAD tissues and paired adjacent normal tissues; scale bars, 100 µm. F, G Comparison of PCBP1 detected by IHC staining (F) and qPCR (G) between tumour and peritumoral tissues and patients with different tumour sizes, N staging and tumour stages. H Kaplan–Meier analysis of overall survival was stratified by protein expression levels of PCBP1. I Kaplan–Meier analysis of overall survival was stratified by mRNA expression levels of PCBP1. *p < 0.05; **p < 0.01; ns, not significant
Fig 2: PCBP1/DKK1/ß-catenin regulates migration and EMT in LUAD cells. A Western blotting analysis of the expression of ß-catenin, phosphor-ß-catenin, Vimentin, Claudin-1, PCBP1 and Tubulin. B shPCBP1 A549 cell migration was estimated by Transwell assays. C The knockdown efficiency of DKK1 in A549 cells was determined by RT–qPCR analyses. D Western blot assays were used to examine the expression levels of DKK1, ß-catenin, phospho-ß-catenin, Vimentin, Claudin-1, PCBP1 and Tubulin in A549 control, A549 PCBP1-OE, A549 PCBP1-OE + siDKK1#1, and A549 PCBP1-OE + siDKK1#2 cells. (E) Cell migration was determined by Transwell assay in each group. *p < 0.05; **p < 0.01; ns, not significant
Fig 3: PCBP1 inhibits tumour growth and metastasis in LUAD in vivo. A Body weight of the mouse A549 cell lung metastasis model. B Representative macroscopic lung images upon necropsy of mice with postimplant shPCBP1 and control A549 cells and HE images. C Quantification of lung metastases in mice bearing either shPCBP1 or control tumours. D Body weight of the mouse H358 cell lung metastasis model. E Representative macroscopic lung images upon necropsy of mice with postimplant shPCBP1 and control H358 cells and HE images. F The number of nodules per lung was quantified by HE staining. G, H A549 and H358 cells stably transfected with control and shPCBP1 were injected subcutaneously into nude mice. Tumour growth curves were plotted. I A549 cells stably transfected with control and PCBP1 were injected subcutaneously into nude mice. Tumour growth curves were plotted. (J) The weights of the excised tumours were measured. *p < 0.05; **p < 0.01; ns, not significant
Fig 4: PCBP1 mediates DKK1 mRNA stability. A Graph based on the above results showing that DKK1 was the key gene. B qPCR analysis of the levels of DKK1 in PCBP1 knockdown and overexpression cells. C Western blot analysis of the levels of DKK1 in PCBP1 knockdown and overexpression cells. D The interaction of PCBP1 with DKK1 was examined by RIP-qPCR in A549 cells. E The interaction of PCBP1 with DKK1 was assessed by RNA pull-down assays followed by western blot analysis and silver staining. F mRNA expression of PCBP1-overexpressing cells and control cells treated with actinomycin D was examined by qPCR. *p < 0.05; **p < 0.01; ns, not significant
Fig 5: The effect of PCBP1 on the biological behaviour of LUAD in vitro. A shPCBP1 A549 cell colony formation ability. B shPCBP1 H358 cell colony formation ability. C PCBP1-OE A549 cell colony formation ability. D–F The proliferation rates of shPCBP1 A549 (D), shPCBP1 H358 (E), and PCBP1-OE A549 (F) cells were measured by IncuCyte ZOOM™. G–I Estimating the cell migration ability in shPCBP1 A549 (G), shPCBP1 H358 (H), and PCBP1-OE A549 (I) cells was performed by the IncuCyte™ Wound Healing assay. *p < 0.05; **p < 0.01; ns, not significant
Supplier Page from Abcam for Anti-PCBP1 antibody